A central Arkansas father is fighting for his life and hoping a stranger could be the answer to his prayers as he searches ...

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...

Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference ...

AstraZeneca PLC through Alexion, AstraZeneca Rare DiseasesUltomiris(ravulizumab) was approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing proteinuria (protein in urine) in adults with primary immunoglobulin A ...

Vera Therapeutics (Nasdaq: VERA) announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in adults with primary IgA nephropathy (IgAN) met statistical ...

ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.

Sparsentan lowered blood pressure more than irbesartan at week 8, with mean differences of -7.2 mmHg systolic and -5.6 mmHg diastolic.

AstraZeneca (NYSE: AZN) announced the US availability of Zegfrovy (sunvozertinib), a treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth ...

BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines ...

A retrospective study of 86 patients with advanced urothelial carcinoma found that baseline kidney function, rather than ...

In a cross-sectional study of 240 patients with chronic kidney disease, higher serum BDNF levels and a ...